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Background
Currently there is little research into initiation and pro-
gression of JIA and there are no reliable predictors of out-
come in early disease, resulting in suboptimal treatment.
Methods
We are undertaking a five-year prospective study of chil-
dren with newly diagnosed and untreated JIA. At least one
knee was involved requiring intra-articular steroid injec-
tion. Detailed clinical, imaging, and laboratory parame-
ters were measured at T0 and 3/12 for 2 years. At outset we
obtained synovial biopsies. We report the outcome on
those children for whom data is available for one year.
Results
At onset, of the first 32 children, 20 had oligoarticular
(OJIA) disease. At one year, 2 had been reclassified as pol-
yarticular (PJIA), 3 as extended oligo. Initially 9 had PJIA
and, at 1 year, this increased to 11. At outset 2 had psori-
atic, and 1 had enthesitis related arthritis.
At one year, all but 3 OJIA patients improved. Physician's
global evaluation (PGE) and ANA status predicted recur-
rent synovitis at the biopsied joint, (p < 0.01) and (p <
0.02) respectively. PGE predicted the frequency of injec-
tions at any joint (p < 0.01).
At one year, all 11 with PJIA had improved clinical and
laboratory parameters.
PJIA showed increased synovial pathology compared with
OJIA (mean vessel score 6.9 vs. 2.6 (p < 0.05), mean B-cell
score 1.7 vs. 1 (p < 0.05)).
Conclusion
In OJIA, PGE and ANA status predict recurrent synovitis.
To date no correlation has been observed between histo-
logical findings and recurrent synovitis in OJIA. We will
report on findings of our enlarged cohort who reach one
year follow-up.
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